Pharmaceutical

Janssen seeks EMA authorisation for urothelial cancer treatment

Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.

Sep 11, 2023 - 20:00
Janssen seeks EMA authorisation for urothelial cancer treatment
Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.
Read the original article

Tags:

Previous Article

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Next Article

Alexion and Verge enter AI-powered drug discovery deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib sh...

Jun 13, 2023

STAT+: Ultima Genomics launching high-end DNA sequencers that can read genome for $100

STAT+: Ultima Genomics launching high-end DNA sequencer...

Jan 30, 2024

Babies born to opioid users have shorter hospital stays with parental involvement: study

Babies born to opioid users have shorter hospital stays...

May 1, 2023